X4 Pharmaceuticals, Inc. · GETTEX:48Q0

X4 Pharmaceuticals, Inc. financial statements

X4 Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue6.50M2.60M0003.00M0000
Cost of revenue5.76M797.0K001.89M1.23M672.0K103.0K195.0K300.0K
Gross profit28.9M1.76M-2.00M-1.99M-1.89M3.00M-672.0K-103.0K-195.0K-300.0K
Research and development72.7M81.6M72.0M61.1M50.6M41.9M30.2M20.3M17.1M17.8M
Selling, general and administrative43.5M61.5M32.1M27.0M24.7M20.9M17.6M18.4M8.01M6.51M
Operating income-86.9M-36.4M-107.5M-87.6M-85.1M-59.9M-51.7M-29.1M-22.2M-24.3M
Depreciation and amortization1.28M796.0K419.0K513.0K499.0K351.0K103.0K103.0K71.0K285.0K
EBITDA-85.6M-35.6M-107.1M-87.1M-84.6M-59.5M-51.6M-29.0M-22.2M-24.1M
Interest expense8.88M8.77M5.78M3.99M3.64M2.69M2.15M720.0K490.0K2.52M
Income before tax-79.2M-37.1M-101.1M-93.8M-88.7M-62.0M-52.8M-33.3M-22.0M-23.0M
Income tax41.0K310.0K78.0K28.0K17.0K148.0K001.87M2.62M
Net income-79.2M-37.5M-101.2M-93.9M-88.7M-62.1M-52.8M-33.3M-22.0M-23.0M
Earnings per share, basic-1.87-5.59-17.07-1.52-3.99-3.09-4.63-79.15-54.58-44.79
Earnings per share, diluted-1.87-5.59-17.07-1.52-3.99-3.09-4.63-79.15-54.58-44.79

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents217.0M55.7M99.2M121.7M81.8M78.7M126.2M8.13M26.7M15.2M
Short-term investments35.9M46.4M15.0M0
Receivables573.0K1.07M01.15M747.0K917.0K02.86M1.61M1.34M
Inventory4.48M2.82M0-747.0K355.0K1.25M
Current assets261.6M112.2M122.1M128.7M87.9M83.3M129.3M9.34M79.5M5.72M
Property, plant and equipment182.0K776.0K745.0K1.10M1.51M1.24M403.0K241.0K421.0K37.0K
Goodwill17.4M17.4M17.4M17.4M17.4M27.1M27.1M0
Total assets290.5M146.4M147.3M155.6M117.2M122.9M160.7M9.94M81.3M7.60M
Accounts payable5.70M8.62M8.95M7.78M4.28M3.14M2.09M2.97M1.89M1.65M
Current liabilities25.8M32.9M22.9M22.3M14.0M11.9M9.45M7.91M10.7M12.1M
Long-term debt76.3M75.4M54.6M32.3M33.1M33.2M20.0M8.31M9.92M10.1M
Total debt75.0M75.0M55.0M32.5M32.5M32.5M20.0M10.0M12.2M15.3M
Total liabilities104.2M124.3M96.2M81.5M52.8M50.1M31.5M21.6M22.5M24.3M
Shareholders' equity186.3M22.1M51.1M74.1M64.4M72.8M129.2M-77.1M-44.5M-23.1M
Shares outstanding90.9M5.70M167.4M121.7M28.1M16.3M16.1M351.7K14.3M16.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-85.6M-130.9M-96.5M-77.1M-70.9M-58.8M-48.1M-25.4M-21.3M-21.6M
Capital spending0-326.0K-60.0K-103.0K-615.0K-1.36M-174.0K0-378.0K-73.0K
Free cash flow-85.6M-131.2M-96.6M-77.2M-71.5M-60.2M-48.2M-25.4M-21.7M-21.7M
Cash from investing8.15M67.0M-14.9M-103.0K-615.0K-1.36M27.2M0-378.0K-73.0K
Cash from financing238.6M20.3M88.5M117.2M74.2M12.4M140.7M6.87M33.4M18.1M
Dividends paid-12-13.9M-12.4M-20.0M-45.7M
Share buybacks00-2.00M00-1.13M-197.0K-87.0K
Change in cash161.4M-43.8M-22.8M39.9M2.41M-47.4M119.6M-18.6M11.7M-3.67M